Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 1, 2017. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on a single transaction involving the acquisition of ordinary shares.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares following the exercise of options under the ShareSave Plan.
- Transaction Price: £11.31 per share.
- Volume: 238 shares.
- Transaction Date: December 1, 2017.
- Location: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It documents a routine equity compensation event for a specific executive.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a Person Discharging Managerial Responsibilities (PDMR) transaction.
Key Facts for Investor Verification
- Executive Involved: Mr. S Dingemans, Chief Financial Officer.
- Option Grant Date: The exercised options were originally granted on October 29, 2014.
- Transaction Nature: This was an initial notification of an acquisition, not a sale or amendment.
- Financial Impact: The transaction volume (238 shares) is immaterial to the company's overall capital structure.